Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Entera Bio ( (ENTX) ) just unveiled an update.
Entera Bio reported its full-year 2025 results on March 27, 2026, highlighting progress on EB613, its lead oral anabolic osteoporosis therapy, and alignment with the FDA on using total hip bone mineral density as a primary Phase 3 endpoint. The company advanced a streamlined Phase 3 protocol using a single-tablet formulation, supported by Phase 2 data showing rapid bone-strengthening effects and expanded evidence in early postmenopausal women, potentially accelerating approval timelines and broadening access versus injectable treatments.
The company also moved EB612, an oral long-acting PTH tablet for hypoparathyroidism, toward the clinic through an expanded, equally funded collaboration with OPKO and positive preclinical data showing prolonged calcium control. In obesity and metabolic disease, EB618, an oral dual GLP-1/Glucagon tablet, and a GLP-2 program for short bowel syndrome showed promising PK/PD profiles suggesting competitive efficacy and more convenient dosing, while 2025 financials reflected a wider net loss and higher R&D spending, with cash expected to fund operations into the third quarter of 2026.
The most recent analyst rating on (ENTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.
Spark’s Take on ENTX Stock
According to Spark, TipRanks’ AI Analyst, ENTX is a Neutral.
The score is held back primarily by weak financial performance (minimal/declining revenue, persistent losses, and cash burn) and bearish technicals (below major moving averages with negative MACD). Offsetting support comes from low leverage/improved equity and positive corporate developments (expanded OPKO collaboration and FDA Phase 3 agreement), while valuation signals are limited due to negative earnings and no dividend.
To see Spark’s full report on ENTX stock, click here.
More about Entera Bio
Entera Bio Ltd. is a clinical-stage biotechnology company focused on developing oral peptide therapies, positioning itself as a leader in converting injectable biologics into tablet formulations. Its pipeline targets major endocrine and metabolic diseases, including osteoporosis, hypoparathyroidism, obesity, metabolic syndromes and rare gastrointestinal disorders, often in collaboration with OPKO Health, Inc.
Average Trading Volume: 208,237
Technical Sentiment Signal: Sell
Current Market Cap: $47.23M
Learn more about ENTX stock on TipRanks’ Stock Analysis page.